VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 404 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2016. The put-call ratio across all filers is 0.94 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q2 2018 | $688,000 | +42.1% | 29,618 | +27.2% | 0.03% | +31.8% |
Q1 2018 | $484,000 | 0.0% | 23,277 | 0.0% | 0.02% | 0.0% |
Q4 2017 | $484,000 | -73.6% | 23,277 | -81.8% | 0.02% | -69.9% |
Q3 2017 | $1,836,000 | -17.3% | 128,095 | -0.2% | 0.07% | -22.3% |
Q2 2017 | $2,220,000 | +57.4% | 128,305 | +0.4% | 0.09% | +54.1% |
Q1 2017 | $1,410,000 | -16.0% | 127,796 | +10.6% | 0.06% | -24.7% |
Q4 2016 | $1,678,000 | -60.6% | 115,556 | -33.4% | 0.08% | -63.5% |
Q3 2016 | $4,262,000 | +22.9% | 173,588 | +0.8% | 0.22% | +14.4% |
Q2 2016 | $3,467,000 | -77.6% | 172,134 | +12.8% | 0.19% | -81.4% |
Q4 2015 | $15,509,000 | – | 152,572 | – | 1.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |